Douglas T. Sheehy Sells 1,905 Shares of Aimmune Therapeutics, Inc. (AIMT) Stock

Aimmune Therapeutics, Inc. (NASDAQ:AIMT) insider Douglas T. Sheehy sold 1,905 shares of Aimmune Therapeutics stock in a transaction dated Thursday, November 9th. The stock was sold at an average price of $33.00, for a total transaction of $62,865.00. Following the completion of the sale, the insider now owns 1,905 shares of the company’s stock, valued at approximately $62,865. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Aimmune Therapeutics, Inc. (NASDAQ:AIMT) opened at $34.26 on Wednesday. Aimmune Therapeutics, Inc. has a 12-month low of $15.97 and a 12-month high of $37.50.

Aimmune Therapeutics (NASDAQ:AIMT) last issued its earnings results on Monday, November 6th. The biotechnology company reported ($0.63) EPS for the quarter, beating the consensus estimate of ($0.72) by $0.09. sell-side analysts forecast that Aimmune Therapeutics, Inc. will post -2.63 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Douglas T. Sheehy Sells 1,905 Shares of Aimmune Therapeutics, Inc. (AIMT) Stock” was originally posted by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this article on another domain, it was copied illegally and republished in violation of international copyright & trademark laws. The correct version of this article can be read at https://transcriptdaily.com/2017/11/15/douglas-t-sheehy-sells-1905-shares-of-aimmune-therapeutics-inc-aimt-stock.html.

Several analysts have weighed in on the stock. Wedbush reiterated an “ourperform” rating and issued a $42.00 price objective on shares of Aimmune Therapeutics in a research note on Monday, August 14th. BidaskClub cut shares of Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. Zacks Investment Research upgraded shares of Aimmune Therapeutics from a “hold” rating to a “buy” rating and set a $34.00 price objective for the company in a research note on Wednesday, November 8th. Piper Jaffray Companies set a $38.00 price objective on shares of Aimmune Therapeutics and gave the stock a “buy” rating in a research note on Thursday, July 27th. Finally, Credit Suisse Group lifted their price objective on shares of Aimmune Therapeutics from $36.00 to $45.00 and gave the stock an “outperform” rating in a research note on Monday, October 23rd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $46.75.

Several large investors have recently modified their holdings of AIMT. American International Group Inc. raised its position in shares of Aimmune Therapeutics by 7.1% in the 1st quarter. American International Group Inc. now owns 16,184 shares of the biotechnology company’s stock valued at $352,000 after buying an additional 1,070 shares in the last quarter. Teachers Advisors LLC raised its position in shares of Aimmune Therapeutics by 2.6% in the 1st quarter. Teachers Advisors LLC now owns 44,349 shares of the biotechnology company’s stock valued at $964,000 after buying an additional 1,120 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Aimmune Therapeutics by 30.5% in the 1st quarter. Vanguard Group Inc. now owns 2,199,858 shares of the biotechnology company’s stock valued at $47,803,000 after buying an additional 513,803 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Aimmune Therapeutics by 5.3% in the 1st quarter. Geode Capital Management LLC now owns 207,210 shares of the biotechnology company’s stock valued at $4,502,000 after buying an additional 10,461 shares in the last quarter. Finally, Morgan Stanley raised its position in shares of Aimmune Therapeutics by 38.9% in the 1st quarter. Morgan Stanley now owns 456,311 shares of the biotechnology company’s stock valued at $9,916,000 after buying an additional 127,700 shares in the last quarter. Institutional investors own 72.42% of the company’s stock.

Aimmune Therapeutics Company Profile

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Insider Buying and Selling by Quarter for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply